The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Trial updates in myeloma: COLUMBA and POLLUX
Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, highlights some of the recent study updates in myeloma including a body-weight subgroup analysis of the COLUMBA study (NCT03277105) which compared subcutaneous (SC) vs intravenous daratumumab in patients with relapsed/refractory multiple myeloma. The analysis concluded that higher SC daratumumab concentrations in patients ≤65 kg had no clinically relevant effect on safety suggesting no weight-based dose individualization is needed. Dr Jenner also discussed data coming from the POLLUX (NCT02076009) study which compared daratumumab, lenalidomide and dexamethasone with lenalidomide and dexamethasone. A significant progression-free survival was observed with the patients taking the daratumumab-containing regimen. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
